Logo

Whatariff.com

Global Tariffs, Categorized

🇺🇸 United States
🌍 Select Country
📦 Progesterone

Progesterone

HS Code:

📦

Overview

Progesterone (HS Code: 2937.23) falls under the category of hormones, prostaglandins, thromboxanes, and leukotrienes, natural or reproduced by synthesis. It is a critical steroid hormone used primarily in hormone replacement therapy, contraception, and treatment of various reproductive disorders. Progesterone and its derivatives are essential in pharmaceutical applications, with a growing demand driven by women's health initiatives and advancements in reproductive medicine. Global trade in progesterone is influenced by production capabilities, regulatory frameworks, and healthcare demands.

Total Trade Volume

USD 320 million

Data from 2022

Source

United Nations Comtrade Database & International Trade Centre (ITC)

Tariff Analysis

Average Rate

5.2%

Highest Rate

12% (imposed by certain developing economies)

Lowest Rate

0% (under free trade agreements like EU-USMCA)

Common Restrictions

  • Import quotas in select countries to protect domestic pharmaceutical industries
  • Stringent regulatory requirements for pharmaceutical-grade progesterone
  • Licensing requirements for hormone-based products
  • Anti-dumping duties in regions with high import competition

Market Trends

Rising demand for hormone replacement therapy (HRT)

Increased imports in aging populations, particularly in North America and Europe, boosting trade volumes by 8% annually

2021-2022

Growth in generic progesterone formulations

Led to competitive pricing and higher export volumes from countries like India and China, reshaping market shares

2020-2022

Stricter regulatory standards for hormone products

Increased compliance costs for exporters, slowing trade growth in markets with stringent health regulations like the EU

2022

Recent Developments

EU Updates GMP Standards for Hormonal Drugs

The European Union introduced stricter Good Manufacturing Practices (GMP) for hormonal drugs, including progesterone, to ensure product safety and traceability.

March 2023

Exporters to the EU market face higher compliance costs, potentially reducing trade volumes from non-compliant manufacturers.

US-China Trade Agreement on Pharmaceuticals

A bilateral agreement reduced tariffs on certain pharmaceutical intermediates, including progesterone derivatives, to encourage trade.

January 2023

Boosted Chinese exports to the US by approximately 5%, strengthening supply chains for progesterone-based products.

India Expands Production Capacity

Major Indian pharmaceutical companies announced investments in progesterone synthesis facilities to meet global demand.

July 2022

Positioned India as a key supplier, increasing its market share in the global progesterone trade by 3% in 2022.